Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315
An Ascending Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 Administered Orally to Healthy Young Adult and Elderly Subjects
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Wyeth is now a wholly owned subsidiary of Pfizer
- Postmenopause · Aug 2010
- Ankylosing Spondylitis · Jul 2010
- Rheumatoid Arthritis · Phase PHASE4 · May 2010
- Fractures · Phase PHASE2/PHASE3 · Mar 2010
- Hemophilia A · Phase PHASE3 · Dec 2009
See all terminations from Wyeth is now a wholly owned subsidiary of Pfizer
Other Alzheimer Disease trials with similar outcome
This PHASE1 trial investigates Alzheimer Disease and is currently terminated or withdrawn. Wyeth is now a wholly owned subsidiary of Pfizer leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jun 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .